Related Experiment Videos
Selective cancer cell apoptosis induced by FTY720; evidence for a Bcl-dependent pathway and impairment in ERK
Haruhito Azuma1, Shigeo Horie, Satoru Muto
1Department of Urology, Osaka Medical College, Takatsuki, Osaka, 569-8686, Japan.
Background:
FTY720 is a unique immunosuppressant that induces apoptosis in activated lymphocytes, but not in other hematopoietic cells. We conducted the present study to investigate its anticancer effect and molecular pathway in inducing apoptosis using murine breast cancer models.
Materials And Methods:
The difference in drug susceptibility to FTY720 between cancer cells and non-cancer cells was examined by MTT assay and cell growth assay. FTY720-induced apoptosis was determined by electron microscopy and DNA electrophoresis, and its molecular pathway was evaluated by Western blot analysis. We then tested in vivo the effect of this agent using two murine breast cancer models.
Results:
FTY720 treatment induced selective cancer cell apoptosis in vitro at a concentration of less than 10 microM. In vivo tumor growth was significantly prevented with induction of apoptosis in both models without any severe systemic adverse reactions. The evaluation of intracellular protease activity demonstrated that FTY720-induced apoptosis was mediated by a Fas-independent, Bcl-associated signal transduction pathway. Inhibition of extracellular signal-regulated kinase (ERK) activity may be involved in its underlying mechanism of action.
Conclusion:
FTY720 may be a promising candidate for a new anticancer therapy, which potentially induces selective apoptosis in cancer cells.
Insights
FTY720, an immunosuppressant, selectively induces cancer cell apoptosis, offering a potential new anticancer therapy with minimal adverse effects in preclinical models.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- FTY720 is an immunosuppressant known to induce apoptosis in activated lymphocytes.
- Its selective action on lymphocytes suggested potential for targeted cancer therapy.
Purpose of the Study:
- To investigate the anticancer effects of FTY720.
- To elucidate the molecular pathways involved in FTY720-induced apoptosis in cancer cells.
- To evaluate FTY720 efficacy in murine breast cancer models.
Main Methods:
- In vitro drug susceptibility assays (MTT, cell growth).
- Apoptosis determination (electron microscopy, DNA electrophoresis).
- Molecular pathway analysis (Western blot, protease activity).
- In vivo efficacy testing in two murine breast cancer models.
Main Results:
- FTY720 induced selective cancer cell apoptosis in vitro at concentrations <10 microM.
- Significant tumor growth inhibition was observed in vivo with minimal systemic adverse reactions.
- FTY720-induced apoptosis was Fas-independent, involving Bcl-associated signaling and potentially inhibiting extracellular signal-regulated kinase (ERK) activity.
Conclusions:
- FTY720 demonstrates selective cancer cell apoptosis induction.
- FTY720 shows promise as a novel anticancer therapeutic agent.
- Further investigation into its molecular mechanisms is warranted.